Otsuka Pharmaceutical Co., Ltd. has entered an agreement in which Otsuka America, Inc., its U.S. subsidiary, will acquire Avanir for $3.5 billion in cash. Avanir, based in Southern California, is a biopharma company specializing in CNS diseases, and employs approximately 500 people.   Avanir developed and launched NUEDEXTA (dextromethorphan hydrobromide/quinidine sulfate) in the U.S. in 2011 as the first and only approved treatment for the neurologic disease pseudobulbar affect (PBA). Sales of N...